According to Gen Consulting Company, the global oncology companion diagnostics market is projected to reach USD 8,711 million, recording a CAGR of approximately 13.6 percent from 2022 to 2028.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global oncology companion diagnostics market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the oncology companion diagnostics industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the solution, technology, indication, end user, and region. The global market for oncology companion diagnostics can be segmented by solution: consumables, instruments, services. Oncology companion diagnostics market is further segmented by technology: immunohistochemistry (IHC), polymerase chain reaction (PCR), next-generation sequencing (NGS), others. Based on indication, the oncology companion diagnostics market is segmented into: breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, others. On the basis of end user, the oncology companion diagnostics market also can be divided into: contract research organization (CRO), laboratories, pharmaceutical & biopharmaceutical companies, others. Oncology companion diagnostics market by region is categorized into: North America, Asia Pacific, Europe, Rest of the World (ROW).

By solution:
– consumables
– instruments
– services

By technology:
– immunohistochemistry (IHC)
– polymerase chain reaction (PCR)
– next-generation sequencing (NGS)
– others

By indication:
– breast cancer
– colorectal cancer
– gastric cancer
– lung cancer
– melanoma
– others

By end user:
– contract research organization (CRO)
– laboratories
– pharmaceutical & biopharmaceutical companies
– others

By region:
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)

The global oncology companion diagnostics market report offers detailed information on several market vendors, including Abbott Laboratories, Inc., Agilent Technologies, Inc., bioMerieux SA, Danaher Corporation, F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc., Guardant Health, Inc., ICON plc, Illumina, Inc., Invitae Corporation, Invivoscribe Technologies, Inc., Myriad Genetics, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific, Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global oncology companion diagnostics market.
– To classify and forecast the global oncology companion diagnostics market based on solution, technology, indication, end user, region.
– To identify drivers and challenges for the global oncology companion diagnostics market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global oncology companion diagnostics market.
– To identify and analyze the profile of leading players operating in the global oncology companion diagnostics market.

Why Choose This Report
– Gain a reliable outlook of the global oncology companion diagnostics market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.